![]() | |
Clinical data | |
---|---|
Trade names | Cervagem |
Other names | methyl (E)-7-[(1R,2S,3R)-3-hydroxy-2-[(E,3R)-3-hydroxy-4,4-dimethyl-oct-1-enyl]-5-oxo-cyclopentyl]hept-2-enoate |
AHFS/Drugs.com | International Drug Names |
Pregnancy category |
|
Routes of administration | Pessary |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.058.869 |
Chemical and physical data | |
Formula | C23H38O5 |
Molar mass | 394.552 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Gemeprost (16, 16-dimethyl-trans-delta2 PGE1 methyl ester) is an analogue of prostaglandin E1.
Clinical use
It is used as a treatment for obstetric bleeding.[citation needed]
It is used with mifepristone to terminate pregnancy up to 24 weeks gestation.[2]
Side effects
Vaginal bleeding, cramps, nausea, vomiting,[3] loose stools or diarrhea,[3] headache, muscle weakness; dizziness; flushing; chills; backache; dyspnoea; chest pain; palpitations and mild pyrexia.[3] Rare: Uterine rupture, severe hypotension, coronary spasms with subsequent myocardial infarctions.[citation needed]
References
- ^ "Cervagem 1 mg Pessary - Summary of Product Characteristics (SmPC)". (emc). 16 August 2019. Retrieved 7 September 2020.
- ^ Bartley J, Brown A, Elton R, Baird DT (October 2001). "Double-blind randomized trial of mifepristone in combination with vaginal gemeprost or misoprostol for induction of abortion up to 63 days gestation". Human Reproduction. 16 (10): 2098–102. doi:10.1093/humrep/16.10.2098. PMID 11574498.
- ^ a b c Aronson, J. K. (2015). Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions. Elsevier Science. p. 524. ISBN 978-0-4445-3716-4.
External links
- "Gemeprost". Drug Information Portal. U.S. National Library of Medicine.